All In Biotech

Drug Trial Radar · NCT05794191

A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV

Assessment of 13-valent Pneumococcal Conjugate Vaccine Effectiveness Among People With HIV in the United States

Last checked: Nov 19, 2026Latest source record: Oct 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

350,399

Actual

Start

Mar 22, 2023

Primary completion

Aug 15, 2024

Study completion Aug 15, 2024

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Apr 3, 2023

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about how well a vaccine (Prevnar 13, PCV13) works in preventing disease in adults with HIV. The diseases studied are pneumonia. Mostly the ones caused by the bacteria - pneumococcus. This study also evaluates the type of pneumonia that is spread into the bloodstream. All participants in the study will be identified in health care databases. Adults with HIV will be identified by looking for a medical diagnosis that has confirmed HIV from the databases. Vaccination will be identified in the databases by looking for vaccine administration or for PCV13. Participants will be followed in the databases to see if they have one of the diseases mentioned above or not. The number of vaccinated participants with the diseases will be compared to the number participants without the vaccines but with the diseases. This will help to understand how well the vaccine worked.

Conditions

  • HIV
  • Pneumonia
  • Infections, Pneumococcal

Interventions

  • Vaccine AdministrationBiological

    PCV13 administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PCV13 Vaccine Effectiveness (VE) for First Event of Invasive Pneumococcal Disease (IPD): Overall Follow-upTime frame: From index date to the earliest of death, end of health plan enrollment or end of study period (maximum up to 8.25 years)
  2. VE for First Event of IPD at 0-3 Years of Follow-upTime frame: 0 to 3 years of follow up
  3. VE for First Event of IPD at 3-5 Years of Follow-upTime frame: 3 to 5 years of follow up
  4. VE for First Event of IPD at 5-7 Years of Follow-upTime frame: 5 to 7 years of follow up
  5. PCV13 VE for First Event of Pneumococcal Pneumonia (PP): Overall Follow-upTime frame: From index date to the earliest of death, end of health plan enrollment or end of study period (maximum up to 8.25 years)
  6. VE for First Event of PP at 0-3 Years of Follow-upTime frame: 0 to 3 years of follow up
  7. VE for First Event of PP at 3-5 Years of Follow-upTime frame: 3 to 5 years of follow up
  8. VE for First Event of PP at 5-7 Years of Follow-upTime frame: 5 to 7 years of follow up
  9. PCV13 VE for First Event of All-cause Pneumonia (ACP): Overall Follow-upTime frame: From index date to the earliest of death, end of health plan enrollment or end of study period (maximum up to 8.25 years)
  10. VE for First Event of ACP at 0-3 Years of Follow-upTime frame: 0 to 3 years of follow up
  11. VE for First Event of ACP at 3-5 Years of Follow-upTime frame: 3 to 5 years of follow up
  12. VE for First Event of ACP at 5-7 Years of Follow-upTime frame: 5 to 7 years of follow up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pfizer

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.